$CRD-A

CRAWFORD & CO (CRD-A): Results of Operations and Financial Condition

CRAWFORD & CO (CRD-A) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 crda-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Crawford & Company® 5335 Triangle Parkway Peachtree Corners, GA 30092 FOR IMMEDIATE RELEASE CRAWFORD & COMPANY REPORTS 2026 SECOND QUARTER RESULTS Strong Earnings Growth Driven by International Operations and Broadspire Quart

Original reporting
Published Aug 3, 2026, 8:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CRD-A
Bullish
high confidence
Mentioned
$CRD-A
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRD-ABullishMed
01

Why it matters

The filing is a primary earnings disclosure with concrete profitability metrics and a capital return action (dividend increase). Segment detail indicates mixed drivers: International and Broadspire improved, while U.S. Property and Casualty declined due to lower weather-related claims and staffing/referral dynamics.

02

Market read

Traders can update near-term expectations for earnings power and capital return based on the reported EPS growth and the dividend increase, while monitoring weather-claims sensitivity highlighted by management.

03

What to watch

The release emphasizes weather-related claims volume and FX impacts; traders may need to separate underlying constant-dollar trends from one-off FX and weather variability when modeling H2.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 3, 2026

Background

The 8-K includes Exhibit 99.1 with Crawford & Company’s Q2 2026 financial results and segment performance, plus management commentary on strategy and dividend policy.

Company-level read

Ticker impact

$CRD-ABullishHigh confidence
Context

Crawford & Company reported 2026 Q2 results, including net income of $13.4M and GAAP diluted EPS of $0.27 for CRD-A, plus a dividend increase to $0.08.

Expected impact

Likely modest positive bias for the next few sessions as dividend and EPS growth are tangible, but weather-claims commentary may cap upside.

Evidence & confidence

The filing discloses specific GAAP and non-GAAP profitability improvements versus the prior year and a board-approved dividend increase, both direct valuation inputs; however, segment revenue declines in U.S. Property and Casualty highlight offsetting pressure.

Market effects

Provides a read-through on insurance services demand sensitivity to weather-related claims volume and the resilience of disability/medical management revenue streams.

International results improved on higher weather-related activity in Australia and Asia, suggesting regional weather patterns are a key driver.

Limited broader macro linkage; primarily company-specific performance across U.S. and international operations.

Counterpoint

Despite EPS growth, U.S. Property and Casualty revenues fell sharply year over year, implying the consolidated strength may be partially offset by weaker domestic demand.

Key entities

  • Crawford & Company

    Reported Q2 2026 revenues, GAAP and non-GAAP earnings, segment results, and increased quarterly dividend to $0.08 per share.

  • Broadspire

    Disability and medical management segment with higher revenues and improved operating margin in Q2 2026.

  • International Operations

    International segment where revenues and operating earnings increased, driven by weather-related activity and improved operating results.

Related articles

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$GXOMed

GXO Logistics Q2 Earnings Call Highlights

GXO Logistics reported Q2 results and said it secured over $1 billion in expected incremental new-business revenue for 2026 and about $353 million for 2027. Management cited a $2.7 billion sales pipeline after quarter end. Operating cash flow was $76 million, free cash flow positive $12 million, cash $769 million, and net leverage 2.6x. GXO plans to target EBIT margins above 6% and deploy AI across ~50 sites in 2026.

$GRNDMed

Grindr Q2 Earnings Call Highlights

Grindr (NYSE:GRND) said free users remain central to its strategy, while AI tools are boosting engineering productivity. Management estimated engineering output rose about 2.5x from July 2025 to April 2026 with similar headcount, supporting a 39% to 42% adjusted EBITDA margin outlook. EDGE AI premium tier rollout is planned for later in fall; operating expenses ex cost of revenue were $71M vs $53M.

$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.